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Human Immunodeficiency Virus (HIV), a retrovirus, is
the etiological agent of acquired immunodeficiency syn-
drome (AIDS). AIDS is characterized by the failure of
the immune system to protect against not only HIV but
also common secondary viral and bacterial infections.
Viruses such as HIV-1 are intracellular pathogens that
require host cell machinery to maintain and generate
new progeny. In that process, viruses disturb the normal
components of intrinsic immune responses within
infected cells. After HIV infection, the expression of var-
ious cellular restriction factors is notably up-regulated
due to interferon activation, partly because genes for
most of these restriction f a c t o r ss u c ha sA P O B E C 3 ,
TRIM, BST2/Tetherin, contain interferon-responsive
promoters. Importantly, these molecules have been
focused on for both elite controllers as well as long-
term non-progressor AIDS patients.
The best characterized HIV restriction factors are
encoded by the APOBEC3 and TRIM gene families. The
interplay between these cellular and viral proteins appears
to be an important factor in deciding the ultimate disease
outcome. Interestingly, HIV has also armed itself to coun-
ter various cellular intrinsic defense mechanisms, thereby
overcoming the intrinsic responses mounted by the host.
Therefore, today there is an intense effort in the HIV/
AIDS field to define both important host-encoded antiviral
restriction factors and viral counter-defense mechanisms
that play key roles in the pathogenesis. Along these lines,
the list of both restriction factors (proteins that counter
specific viral proteins) and repressive factors (inhibitors of
HIV life cycle) has been growing continuously. These fac-
tors not only include APOBECs, TRIM5a, p21/waf1, and
SAMHD1, which act on the incoming virus [1], but also
TRIM22, TRIM28/KAP1, and BST2/Tetherin, which exert
their effect on post integration, assembly and budding.
In a recent manuscript by Liu et al., the authors utilized
an siRNA screening method to knockdown expression of
19,121 human genes [2]. They specifically looked for
knockdown of restriction factors that would rescue the
early stages of HIV replication from post entry to integra-
tion. The assay utilized viral pseudotypes HIV89.6R and
HIV8.2N which are capable of a single round of infection.
To optimize the screening, they used negative control
siRNAs targeting cyclophilin B, PLK1 and GFP in target
HeLa-CD4 cells. They identified 114 genes that affected a
wide range of cellular activities that could be classified as
genes that defend against retroviral invasion. These fac-
tors fall into various functional categories such as recep-
tor signaling, vesicle trafficking, transcription, mRNA
processing, DNA/RNA surveillance, cross-nuclear mem-
brane transport and ubiquitination. Interestingly, they
did not observe the presence of the classical RNA-recog-
nizing PRRs such as toll like receptors TLR3, 7 or 8 or
RIG-1 like receptors or MDA-5 in their screening. Genes
such as AP2M1, DNM2, SETDB1, PAF1, CTR9 and RTF1
were identified and further characterized. Some of the
gene products were previously shown to be involved in
the regulation of endocytosis (AP2M1 and DNM2), HIV
pre-integration complex transportation from cytoplasm
to nucleus (NPIP, an interacting partner of nuclear pore
components such as NUP62), PAF 1 complex and pro-
tein methylase (SETDB1).
Their detailed investigation demonstrated the role of
PAF1 complex as an important repressive factor during
intrinsic defense against HIV infection. Specifically, the
PAF1 complex appears to block HIV replication during
the early events from post entry to integration of proviral
DNA into host genome. Intriguingly, they found that
PAF1 complex is present ubiquitously in various cell
lineages, which are common targets of HIV that include
monocytes, macrophages and T lymphocytes. Moreover,
PAF1 complex not only effectively represses HIV infec-
tion but also inhibits infection of evolutionarily similar
retroviruses such as HIV-2 and SIV.
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enzymatic activity as lysine methyltransferase. The
SETDB1 possesses specificity for lysine 9 of histone H3
and plays an important role in silencing transcription by
depositing specific histone marks, namely H3K9me2-3
during cell differentiation [3,4]. Additionally, SETDB1
has been shown to induce Tat methylation, which results
in reduced viral production [5], and on the other hand
methyl transferase inhibitors (similar to siRNA used
here) lead to the enhancement of virus production [6].
The finding of SETDB1 in the screen of Li et al. further
establishes the role of TRIM28 during proviral integra-
tion, which it primarily executes by recruiting SETDB1 to
the pre-integration complex [7]. It will be interesting to
determine how this enzyme regulates the activity of other
viral pre-integration proteins such as RT, Gag or IN on
specific lysine residues, which could acquire both acety-
lating and methylation marks.
In another article by Woods at al., the authors con-
firmed the role of HECT domain and RCC1-like domain-
containing protein 5 (HERC5), an interferon inducible
gene that restricts the early stages of HIV assembly [8].
Cells expressing HERC5 released 4.0-fold less infectious
virus than the control cells after a single round of replica-
tion. Furthermore using published databases, the authors
found that HERC5 expression is significantly increased in
patients in acute and chronic stages of infection but not
in non-progressors. Collectively, the data are consistent
with previous reports [9-11], where HERC5 restriction is
different from the well established anti-HIV-1 activities
of ISG15-only expression.
Thus, these studies add a few more candidates to the
ever growing list of HIV repressive and restriction factors
that inhibit HIV life cycle at v a r i o u ss t a g e s( F i g u r e1 ) .
Taken together, these investigations are novel and open
the door for a better understanding of how host cellular
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Figure 1 Two new host repressive factors which inhibit HIV life cycle at different steps. PAF1 complex seems to inhibit early events of
viral life cycle from reverse transcription to integration step. On the other hand HERC5 appears to act at the later part of viral life cycle, that is
during the earlier stage of new viral particle assembly, most probably by regulating the ISGylation of Gag protein of HIV.
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Page 2 of 3factors control infection. Future confirmatory experi-
ments using primary infections of T-cells vs. macro-
phages and field isolate of the virus to elucidate viral
targets for each of these important factors and to elicit
possible escape mutants to their restriction will shed
more light on this fascinating area of research.
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